Sarcoidosis

Medical Clinics of North America

Volumn 89, Issue 4, 2005, Pages 817-828

  Cox, Christopher E ^a   Davis Allen, Angela ^b   Judson, Marc A ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; INFLIXIMAB; LEVAMISOLE; METHOTREXATE; PENTOXIFYLLINE; THALIDOMIDE;

CLINICAL FEATURE; CLINICAL TRIAL; CORYNEBACTERIUM; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; ETHNIC GROUP; GENETIC ANALYSIS; HEALTH CARE ACCESS; HUMAN; NOCARDIA; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; RATING SCALE; REVIEW; RHODOCOCCUS EQUI; SARCOIDOSIS; TREATMENT OUTCOME; TROPHERYMA WHIPPELII;

ADULT; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); SARCOIDOSIS;

EID: 19944420505     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2005.02.006     Document Type: Review

References (52)

1. S. Nagai Pulmonary sarcoidosis: pathogenesis and population differences Intern Med 34 1995 833 838
2. R.P. Baughman, A.S. Teirstein, and M.A. Judson Clinical characteristics of patients in a case control study of sarcoidosis Am J Respir Crit Care Med 164 2001 1885 1889
3. Statement on sarcoidosis Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999 Am J Respir Crit Care Med 160 1999 736 755
4. M.A. Judson, B.W. Thompson, and D.L. Rabin The diagnostic pathway to sarcoidosis Chest 123 2003 406 412
5. J. Yu-Yun Lee Sarcoidosis in Taiwan: clinical characteristics and atypical mycobacteria J Formos Med Assoc 101 2002 749 755
6. B.A. Rybicki, M.J. Maliarik, and M. Major Epidemiology, demographics, and genetics of sarcoidosis Semin Respir Infect 13 1998 166 173
7. B.A. Rybicki, M. Major, and J. Popovich Jr. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization Am J Epidemiol 145 1997 234 241
8. A. Pietinalho, Y. Hiraga, and Y. Hosoda The frequency of sarcoidosis in Finland and Hokkaido, Japan: a comparative epidemiological study Sarcoidosis 12 1995 61 67
9. B.A. Rybicki, and M.C. Iannuzzi Sarcoidosis and human leukocyte antigen class I and II genes: it takes two to tango? Am J Respir Crit Care Med 169 2004 665 666
10. L.A. Hart, M. Conron, and R.M. du Bois Sarcoidosis Int J Tuberc Lung Dis 5 2001 791 806
11. B.A. Rybicki, K.L. Amend, and M.J. Maliarik Photocopier exposure and risk of sarcoidosis in African-American sibs Sarcoidosis Vasc Diffuse Lung Dis 21 2004 49 55
12. L.S. Newman, C.S. Rose, and E.A. Bresnitz A case control etiologic study of sarcoidosis: environmental and occupational risk factors Am J Respir Crit Care Med 170 2004 1324 1330
13. J.M. Reich What is sarcoidosis? Chest 124 2003 367 371
14. B.A. Rybicki, M.C. Iannuzzi, and M.M. Frederick Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS) Am J Respir Crit Care Med 164 2001 2085 2091
15. L.S. Newman, C.S. Rose, and L.A. Maier Sarcoidosis N Engl J Med 336 1997 1224 1234
16. H.L. Israel, P. Karlin, and H. Menduke Factors affecting outcome of sarcoidosis: influence of race, extrathoracic involvement, and initial radiologic lung lesions Ann N Y Acad Sci 465 1986 609 618
17. A. Pietinalho, M. Ohmichi, and Y. Hiraga The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan: a comparative analysis of 571 Finnish and 686 Japanese patients Sarcoidosis Vasc Diffuse Lung Dis 13 1996 159 166
18. S.K. Sharma, and A. Mohan Sarcoidosis: global scenario and Indian perspective Indian J Med Res 116 2002 221 247
19. *1101: a significant risk factor for sarcoidosis in blacks and whites Am J Hum Genet 73 2003 720 735
20. B.A. Rybicki, M.J. Maliarik, and L.M. Poisson The major histocompatibility complex gene region and sarcoidosis susceptibility in African Americans Am J Respir Crit Care Med 167 2003 444 449
21. R.M. Rutherford, F. Staedtler, and J. Kehren Functional genomics and prognosis in sarcoidosis-the critical role of antigen presentation Sarcoidosis Vasc Diffuse Lung Dis 21 2004 10 18
22. M.C. Iannuzzi, M.J. Maliarik, and L.M. Poisson Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans Am J Respir Crit Care Med 167 2003 1225 1231
23. J. Grunewald, A. Eklund, and O. Olerup Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients Am J Respir Crit Care Med 169 2004 696 702
24. G.P. Kucera, B.A. Rybicki, and K.L. Kirkey Occupational risk factors for sarcoidosis in African-American siblings Chest 123 2003 1527 1535
25. D.K. Kajdasz, M.A. Judson, and L.C. Mohr Jr. Geographic variation in sarcoidosis in South Carolina: its relation to socioeconomic status and health care indicators Am J Epidemiol 150 1999 271 278
26. D.K. Kajdasz, D.T. Lackland, and L.C. Mohr A current assessment of rurally linked exposures as potential risk factors for sarcoidosis Ann Epidemiol 11 2001 111 117
27. B. Chang, J. Steimel, and D.R. Moller Depression in sarcoidosis Am J Respir Crit Care Med 163 2001 329 334
28. M.A. Judson, R.P. Baughman, and B.W. Thompson Two year prognosis of sarcoidosis: the ACCESS experience Sarcoidosis Vasc Diffuse Lung Dis 20 2003 204 211
29. D.L. Rabin, M.S. Richardson, and S.R. Stein Sarcoidosis severity and socioeconomic status Eur Respir J 18 2001 499 506
30. D.L. Rabin, B. Thompson, and K.M. Brown Sarcoidosis: social predictors of severity at presentation Eur Respir J 24 2004 601 608
31. K.W. Thomas, and G.W. Hunninghake Sarcoidosis JAMA 289 2003 3300 3303
32. J. Mana, A. Salazar, and F. Manresa Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases Respiration (Herrlisheim) 61 1994 219 225
33. K. Iwai, M. Sekiguti, and Y. Hosoda Racial difference in cardiac sarcoidosis incidence observed at autopsy Sarcoidosis 11 1994 26 31
34. M.A. Judson An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment Chest 115 1999 1158 1165
35. A.F. Shorr, D.B. Davies, and S.D. Nathan Outcomes for patients with sarcoidosis awaiting lung transplantation Chest 122 2002 233 238
36. S. Walker, G. Mikhail, and N. Banner Medium term results of lung transplantation for end stage pulmonary sarcoidosis Thorax 53 1998 281 284
37. H.L. Paz, D.J. McCormick, and S.P. Kutalek The automated implantable cardiac defibrillator: prophylaxis in cardiac sarcoidosis Chest 106 1994 1603 1607
38. S. Paramothayan, and P.W. Jones Corticosteroid therapy in pulmonary sarcoidosis: a systematic review JAMA 287 2002 1301 1307
39. C.E. Cox, J.F. Donohue, and C.D. Brown Health-related quality of life of persons with sarcoidosis Chest 125 2004 997 1004
40. M. Baltzan, S. Mehta, and T.H. Kirkham Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis Am J Respir Crit Care Med 160 1999 192 197
41. S. Paramothayan, T. Lasserson, and E.H. Walters Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis [review] Cochrane Database Syst Rev 3 2003 CD003536
42. A. Pietinalho, P. Tukiainen, and T. Haahtela Early treatment of stage II sarcoidosis improves 5-year pulmonary function Chest 121 2002 24 31
43. M.A. Judson, R.P. Baughman, and A.S. Teirstein Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 16 1999 75 86
44. C.E. Cox, J.F. Donohue, and C.D. Brown The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life Am J Respir Crit Care Med 168 2003 323 329
45. J. De Vries, M. Drent, and G.L. Van Heck Quality of life in sarcoidosis: a comparison between members of a patient organisation and a random sample Sarcoidosis Vasc Diffuse Lung Dis 15 1998 183 188
46. R.M. Wirnsberger, J. de Vries, and M.H. Breteler Evaluation of quality of life in sarcoidosis patients Respir Med 92 1998 750 756
47. J. De Vries, G.L. Van Heck, and M. Drent Gender differences in sarcoidosis: symptoms, quality of life, and medical consumption Women Health 30 1999 99 114
48. J. De Vries, and M. Drent Relationship between perceived stress and sarcoidosis in a Dutch patient population Sarcoidosis Vasc Diffuse Lung Dis 21 2004 57 63
49. R.M. Wirnsberger, M. Drent, and N. Hekelaar Relationship between respiratory muscle function and quality of life in sarcoidosis Eur Respir J 10 1997 1450 1455
50. M. Drent, R.M. Wirnsberger, and M.H. Breteler Quality of life and depressive symptoms in patients suffering from sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 15 1998 59 66
51. J.A. Chang, J.R. Curtis, and D.L. Patrick Assessment of health-related quality of life in patients with interstitial lung disease Chest 116 1999 1175 1182
52. W.J. Martin II, M.C. Iannuzzi, and D.B. Gail Future directions in sarcoidosis research: summary of an NHLBI working group Am J Respir Crit Care Med 170 2004 567 571